The novel compound Hypertril improves eNOS/iNOS expression and enhances NO bioavailability more effectively than conventional β-blockers, stabilizing ECG parameters and restoring energy metabolism.
Does the novel NO-mimetic compound Hypertril improve NO bioavailability and cardioprotection compared to conventional beta-blockers in chronic heart failure?
The novel NO-mimetic beta-blocker Hypertril demonstrates significant cardioprotective potential in experimental models of chronic heart failure by addressing underlying biochemical mechanisms.
Chronic heart failure (CHF) remains a leading cause of global mortality, characterized by profound molecular and biochemical disturbances, including nitric oxide (NO) system dysfunction, mitochondrial impairment, and oxidative stress. While standard therapies such as ACE inhibitors, SGLT2 inhibitors, and beta-blockers address clinical symptoms, their capacity to interrupt the underlying biochemical mechanisms of cardiomyopathy is often limited. This review examines the pathophysiological role of impaired NO production and reactive oxygen species (ROS) accumulation in exacerbating myocardial contractile dysfunction and disease progression. Special focus is directed toward the development of next-generation β1-blockers with multifunctional properties, including antioxidant, NO-mimetic, and antiapoptotic effects. Evidence suggests that the novel compound Hypertril (1-(β-phenylethyl)-4-amino-1,2,4-triazolium bromide) exhibits significant cardioprotective potential. Experimental data indicate that Hypertril improves eNOS/iNOS expression and enhances NO bioavailability more effectively than conventional β-blockers, leading to stabilized ECG parameters and restored energy metabolism. These findings underscore the clinical relevance of developing NO-mimetic agents to optimize the pharmacological management of CHF.
Беленичев et al. (Thu,) conducted a review in Chronic heart failure. Hypertril vs. Conventional β-blockers was evaluated. The novel compound Hypertril improves eNOS/iNOS expression and enhances NO bioavailability more effectively than conventional β-blockers, stabilizing ECG parameters and restoring energy metabolism.